Background: [ 11 C]erlotinib has been proposed as a PET tracer to visualize the mutational status of the epidermal growth factor receptor (EGFR) in cancer patients. For clinical use, a stable, reproducible and high-yielding radiosynthesis method is a prerequisite. In this work, two production schemes for [
Background
The epidermal growth factor receptor (EGFR) belongs to the family of receptor tyrosine kinases and is one of the most frequently overexpressed proteins in malignant tumors (Ciardiello and Tortora 2008) . Therefore, it has become an attractive target for cancer treatment. In this regard, EGFR specific antibodies such as cetuximab (Erbitux®) as well as small molecule tyrosine kinase inhibitors (TKIs) such as gefitinib (Iressa®) and erlotinib (Tarceva®, OSI-774) have been developed. Erlotinib reached marketing authorization in 2004 and belongs to the first-generation reversible TKIs (Cohen et al. 2005) . It is used to treat non-small cell lung cancer (NSCLC) and pancreatic cancer (Singh and Jadhav 2017) . One crucial parameter for prediction of treatment response is the mutational status of the EGFR. In order to identify the subset of patients who will benefit from therapy with erlotinib, positron emission tomography (PET) with [ 11 C]erlotinib has been proposed (Memon et al. 2009; Bahce et al. 2013; Petrulli et al. 2013; Slobbe et al. 2015) . Owing to the short radioactive half-life of carbon-11 (t 1/2 = 20.4 min), a short overall synthesis time is desirable as it determines absolute radiochemical yields and molar activities. Hence, every adaption in the radiosynthesis protocol reducing the synthesis time significantly improves the outcome. Additionally, depending on the intended use of the radiotracer (i.e. preclinical or clinical), different approaches for formulation of the final product may be required. For example, higher doses in an overall larger volume are applied in patients, whereas in small animal studies the volume of injection is very limited and therefore, a higher concentration of the PET tracer is required.
The present study focused on comparing the radiosynthesis of Bahce et al. (2013) and was effectively implemented for preclinical and clinical studies (Traxl et al. 2017; Bauer et al. 2017) . Additionally, a time-efficient HPLC method for quality control (Nics et al. 2018 ) was applied to minimize post-production loss of [ 11 C]erlotinib caused by a time intensive quality control and subsequent decline of molar activity.
Methods

Materials
Unless otherwise stated all chemicals were purchased from Sigma-Aldrich Chemie (Schnelldorf, Germany) or Merck (Darmstadt, Germany) at analytical grade and were used without further purification. The Ni catalyst (Shimalilte Ni reduced, 80/100 mesh) was purchased from Shimadzu (Kyoto, Japan). The precursor 6-O-desmethyl-elotinib (OSI-420; GMP grade) was purchased from Syncom B.V. (Groningen, Netherlands) and the reference compound erlotinib (N-(3-ethinylphenyl)-6,7-bis(2-methoxyethoxy)-quinazolin-4-amine) was obtained from Apollo Scientific (Bredbury, UK). Semi-preparative high performance liquid chromatography (HPLC) column (Chromolith® SemiPrep RP-18e, 100-10 mm; guard column: 10-10 mm) and analytical HPLC column (Chromolith Performance RP-18e, 100-4.6 mm; guard column: 10-4.6 mm) were purchased from Merck (Darmstadt, Germany). The analytical HPLC column for the optimized quality control (XBridge® Shield RP-18; 2.5 μm; 3.0-50 mm) and C18plus SepPak® cartridges for solid phase extraction (SPE) were purchased from Waters (Waters® Associates Milford, MA, USA Conventional analytical HPLC was performed using an Agilent 1260 system (Agilent Technologies GmbH, Santa Clara, CA, USA) equipped with a UV-detector, a BGO detector (Elysia-Raytest, Straubenhardt, Germany) and controlling software Agilent Chemstation or Elysia-Raytest GINA Star. Optimized analytical HPLC for the 1 min quality control run was performed as described elsewhere (Nics et al. 2018) . For the optimization, an analytical HPLC column, X-Bridge BEH Shield RP-18, 4.6 × 50 mm, 2.5 μm, 130 Å (Waters GmbH), was used. The analytical HPLC analyses was performed on a single Agilent 1260 system equipped with a quaternary pump (G1311B), a multi wavelength UV-detector (G1365D), a column oven (G1316A), a manual injector (G1328C), a NaI (Tl) detector from Berthold Technologies (Bad Wildbad, Germany) and GINA Star controlling software (Elysia-Raytest; Straubenhardt, Germany). The osmolality was measured using a Wescor osmometer Vapro® 5600 (Sanova Medical Systems, Vienna, Austria) and pH was measured using a WTW inoLab 740 pH meter (WTW, Weilheim, Germany). Gas chromatography was performed using a 430-GC system (Bruker Daltonik GmbH, Bremen, Germany).
Preparation of the synthesis module
A scheme of the synthesis module is presented in Fig. 1 . All parts prior to HPLCpurification (reactor, HPLC injector, tubing) were rinsed with water and acetone and then dried with a stream of helium. Parts after semi-preparative HPLC (i.e. solid-phase extraction (SPE) tubing, dilution flask, product collection vial, product outlet tubing) were cleaned using ethanol and water. eluted with retention times of 2.5-3.5 min and 4.5-5.5 min (method 1, Fig. 3a ) and 5.2-6.5 min and 9-10 min (method 2, Fig. 3b ), respectively. The [ 11 C]erlotinib product fraction was collected in a bulb and diluted with 100 mL of sterile water. The resulting solution was then pushed through a preconditioned C18 SPE cartridge (10 mL EtOH, 20 mL H 2 O, dried). The cartridge was washed with 10 mL of water and the purified product was eluted with 1.5 mL of ethanol into the product vial. For preclinical use, the EtOH was then removed on a rotary evaporator and the product formulated in in 0.9% aq. saline/0.1 M HCl (100/0.1, v/v) at an approximate concentration of 370 MBq/mL for intravenous injection.
For clinical use, the SPE cartridge was washed with 5 mL 0.9% saline solution, which was collected into the product vial containing 6 mL phosphate-buffer saline (PBS) solution. The resulting solution was transferred through a 22 μm sterile filter into a sterile 25 mL vial containing further 5 mL of 0.9% saline solution. Hence, the final total volume of the product solution was 17.5 mL (containing 8.6% ethanol).
Quality control of [ 11 C]erlotinib
Chemical and radiochemical impurities were detected and quantified using analytical radio-HPLC according to the monograph in the European Pharmacopoeia (Radiopharmaceutical C]erlotinib relative to total radioactivity was determined (threshold ≥95%). Sample chromatograms are given in Fig. 4 . Residual solvents were analysed by GC. Osmolality and pH were determined to assure safe administration using standard methods. Radionuclidic purity was assessed by recording of the corresponding gamma spectrum and additional measurement of the physical half-life. Testing of sterility and concentration of bacterial endotoxins was performed using standard protocols at the Department of Infection Diseases and Tropical Medicine (Medical University of Vienna, Austria).
Results
The fully-automated synthesis and purification of (Nics et al. 2018) ). The molar activity ]erlotinib was greater than 98% and molar activity at EOS was 157 ± 68 GBq/μmol (range:: 65-396 GBq/μmol, 2.2-18.8 nmol erlotinib).
Typical loss during final sterile filtration was <10% of the product activity. Residual acetonitrile as determined by GC was found to be <20 ppm. Osmolality was 303 ± 21 mosmol/kg and pH was 7.5 ± 0.1. Concentration of endotoxins was found below 1.0 EU/mL and all samples passed the test for sterility. All quality parameters were in accordance with the standards for parenteral human application. The entire quality control process (except for tests for residual solvents, endotoxins and sterility) was completed within 3 min using the optimized analytical HPLC system. ) and bases (NaH and TBAH) for the deprotonation of the alcohol functionality of the precursor (Table 2 ). The highest, but also most fluctuating molar activities have been reported by Bahce et al. (2013) (Table 2) . However, the [ 11 C]CH 3 I production method is not fully specified in the work by Bahce et al. (2013) , which is an important factor influencing molar activity. The two studies which used NaH as base for the synthesis of [
11 C]erlotinib (Memon et al. 2009; Petrulli et al. 2013 ) did not state radiochemical yields. We employed the reaction conditions of Bahce et al. (2013) for setting-up the radiosynthesis of [ 11 C]erlotinib in our laboratories. The usage of CH 3 CN as solvent and TBAH as base led to final product amounts of 2.6 ± 1.3 GBq (method 1) or 0.76 ± 0.27 GBq (method 2), which was considered sufficient for clinical and preclinical use of the radiotracer, so that no further optimization of synthesis parameters was performed. Method 1 afforded higher final product amounts than method 2, due to the possibility to produce higher starting activities with the . In order to compensate the time loss due to the reduction step of [ 11 C]CO 2 in method 1, the flow rate in the semi-preparative HPLC purification was increased from 2.5 mL/min (method 2) to 8 mL/min (method 1). Precursor and product [ 11 C]erlotinib were still sufficiently separated with the increased flow rate and eluted with retention times of 2.5-3.5 min and 4.5-5.5 min, respectively (Fig. 3a) . The shortening of the HPLC purification time in method 1 led to comparable total synthesis times for both methods. C]DASB), the presently employed set-up (method 2) afforded molar activities at EOS up to 1 TBq/μmol. Additional optimization included the setup of an ultra-HPLC system, which reduced the time of the RP-HPLC run of the quality control from 10 to 1 min. (Nics et al. 2018) This reduction in time for the quality control would afford a 27% increase in molar activity at the time of PET tracer administration into a patient, as compared to use of the conventional HPLC system. To ensure that no radioactive impurity is missed, we compared the optimized HPLC method to the conventional assay: all peaks (including impurities), which were detected in the conventional system could also be detected in the same ratios in the improved set-up. Abourbeh et al. (2015) reported an inverse correlation between [ ]erlotinib PET scans during erlotinib therapy as compared to PET scans when they were off therapy (Bahce et al. 2016) . These data suggest that an increase in molar activity of [ 
Conclusion
We compared two different methods for the synthesis of [ ]CH 4 method yielded 1.8-fold higher molar activities, which may be beneficial for improved target-to-non target ratios in EGFR imaging of tumors. In order to keep the time consumption to a minimum, a highly efficient RP-HPLC method was established lasting for not more than 1 min, which can be expected to lead to an increase in molar activity at the time of radiotracer injection into a patient. Availability of data and materials Please contact author for data request.
